Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Addressing disparities in chemotherapy acceptance: barriers and potential solutions

Inimfon Jackson • 30 May 2025
ASCO 2025
General

Inimfon Jackson, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses disparities in chemotherapy acceptance and potential strategies to address them. She emphasizes that the most significant disparities exist in patients on public insurance or with no insurance, as well as non-Hispanic Black patients. Dr Jackson highlights the importance of a multi-pronged approach to address distrust of providers, identify patients at risk, and facilitate informed decision-making. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Inimfon Jackson

Addressing access barriers and guideline-concordant breast cancer care
1:07
Addressing access barriers and guideline-concordant breast cancer care
Inimfon Jackson • 10 Dec 2025
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
2:28
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
Inimfon Jackson • 10 Dec 2025
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
1:53
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
Inimfon Jackson • 30 May 2025
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
0:57
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
Inimfon Jackson • 30 May 2025

Related Videos

Drug price competition and the potential for tendering in oncology care
1:34
Drug price competition and the potential for tendering in oncology care
Daniel Goldstein • 23 Oct 2026
What financial challenges patients and healthcare systems face in oncology?
1:11
What financial challenges patients and healthcare systems face in oncology?
Daniel Goldstein • 23 Oct 2026
How can we enhance the efficacy of TILs therapy in solid tumors?
2:27
How can we enhance the efficacy of TILs therapy in solid tumors?
Paolo Ascierto • 23 Oct 2026
Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals